Crossmark

Disease activity outcomes with different washout periods after switching from natalizumab to an alternative disease-modifying therapy

Published Online: 2020-04-09

Published Print: 2020-08

Authors

Hua, Le H. https://orcid.org/0000-0002-0535-3978
Harris, Haleigh

Conway, Devon

Hersh, Carrie M.
Funding

Funding for this research was provided by:

Sheila and Eric Samson Foundation
License Information

Text and Data Mining valid from 2020-04-09

Version of Record valid from 2020-04-09
More Information

Article History

Received: 10 November 2019

Revised: 13 February 2020

Accepted: 31 March 2020

First Online: 9 April 2020

Compliance with ethical standards

:

: LHH received personal compensation for speaking, consulting, or advisory board activities from Biogen, Genzyme, Genentech, Novartis, Celgene and EMD Serono. HH has nothing to disclose. DC has received research support paid to his institution from Novartis Pharmaceuticals and the National Multiple Sclerosis Society. He has received personal compensation for consulting from Novartis Pharmaceuticals and Tanabe Laboratories. CMH receives personal compensation for speaking and consulting from Genzyme, Genentech, EMD-Serono, Novartis, and Biogen. She has received research support paid to her institution by Biogen, Genentech, and PCORI.

: This study was approved by the local Institutional Review Board of the Cleveland Clinic Foundation.

Document is current